MA56203A - Anticorps humains dirigés contre la protéine morphogénétique osseuse 6 - Google Patents

Anticorps humains dirigés contre la protéine morphogénétique osseuse 6

Info

Publication number
MA56203A
MA56203A MA056203A MA56203A MA56203A MA 56203 A MA56203 A MA 56203A MA 056203 A MA056203 A MA 056203A MA 56203 A MA56203 A MA 56203A MA 56203 A MA56203 A MA 56203A
Authority
MA
Morocco
Prior art keywords
human antibodies
antibodies against
bone morphogenetic
morphogenetic protein
against bone
Prior art date
Application number
MA056203A
Other languages
English (en)
French (fr)
Inventor
Sarah J Hatsell
Vincent J Idone
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA56203A publication Critical patent/MA56203A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA056203A 2019-06-12 2020-06-09 Anticorps humains dirigés contre la protéine morphogénétique osseuse 6 MA56203A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962860597P 2019-06-12 2019-06-12

Publications (1)

Publication Number Publication Date
MA56203A true MA56203A (fr) 2022-04-20

Family

ID=71944214

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056203A MA56203A (fr) 2019-06-12 2020-06-09 Anticorps humains dirigés contre la protéine morphogénétique osseuse 6

Country Status (6)

Country Link
EP (1) EP3983436A1 (https=)
JP (2) JP7807238B2 (https=)
AU (1) AU2020292246A1 (https=)
CA (1) CA3141266A1 (https=)
MA (1) MA56203A (https=)
WO (1) WO2020251924A1 (https=)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
EP2136788B1 (en) 2007-03-30 2011-10-26 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US20140086919A1 (en) 2012-09-24 2014-03-27 Herbert Y. Lin Methods and compositons for regulating iron homeostasis by modulation of bmp-6
AU2016211890B2 (en) * 2008-11-13 2018-03-22 The General Hospital Corporation Methods and Compositions for Regulating Iron Homeostasis by Modulation of BMP-6
AR093620A1 (es) 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
UY36449A (es) * 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
GB2550114A (en) 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists

Also Published As

Publication number Publication date
EP3983436A1 (en) 2022-04-20
US20220251184A1 (en) 2022-08-11
CA3141266A1 (en) 2020-12-17
AU2020292246A1 (en) 2022-01-27
WO2020251924A1 (en) 2020-12-17
JP7807238B2 (ja) 2026-01-27
JP2025138816A (ja) 2025-09-25
JP2022537142A (ja) 2022-08-24

Similar Documents

Publication Publication Date Title
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
EP3618871A4 (en) FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
EP3634314A4 (en) DOCKING ARRANGEMENT FOR HEART VALVE PROSTHESIS
EP4400083C0 (en) BONE JOINT IMPLANTS
EP3937806C0 (en) SPINAL IMPLANT MADE OF COMPOSITE MATERIAL
EP3720368A4 (en) BONE FIXATION ARRANGEMENT, IMPLANTS AND METHOD OF USE
EP3835418A4 (en) Novel crispr-associated protein and use thereof
EP3865509A4 (en) RECOMBINANT ANTIBODY TO HUMAN HEART TROPONIN I
IL284807A (en) Antibodies specific to human nectin-2
EP3837286A4 (en) ANTIBODIES TO HUMAN ZNT8
IL290660A (en) Therapeutic fusion proteins
EP3721828A4 (en) FIXATION OF A DENTAL IMPLANT
EP3684191A4 (en) CORN PROTEIN RETENTION DURING EXTRACTION
EP3787700C0 (en) SYNTHETIC BONE GRAFT
EP3673100A4 (en) DYNAMIC LIBRARIES FOR HUMAN ANTIBODIES WITH A LIGHT CHAIN
EP3752102A4 (en) SPINE IMPLANT SYSTEM
EP3858866A4 (en) GLP1-FC FUSION PROTEIN AND ASSOCIATED CONJUGATE
EP3875114A4 (en) ANTIBODIES AGAINST HUMAN FN14
EP3897362A4 (en) INTELLIGENT BONE AND SOFT TISSUE CLASSIFIER
ZA202109744B (en) Anti-connective tissue growth factor antibody and application thereof
EP3833691A4 (en) HUMAN PD-L1 ANTIBODIES
EP3955963A4 (en) ANTIBODIES TARGETED TO HUMAN CD47
EP3903723A4 (en) Dental implant handset
EP3805389A4 (en) ANTIBODIES TO HUMAN TLR7
EP4013445A4 (en) Therapeutic protein compositions and methods